Safety Study of Zimura™in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)
Epistemonikos ID: 460dfb3c7a980f0dc52a3a86642cfe0a4e3b3ffc
First added on: May 14, 2024